Merck's (MRK +0.6%) potential blockbuster insomnia drug suvorexant performs well in two-late...
Wednesday, June 13, 2012, 11:36 AM ETMerck's (MRK +0.6%) potential blockbuster insomnia drug suvorexant performs well in two-late stage trials, helping patients fall asleep faster and stay in dreamland for longer than a placebo. Suvorexant is designed to minimize morning grogginess, although the major side effects were headaches and...tiredness. Still, Merck intends to file for FDA approval this year.
HEALTHCARE ETFs IN FOCUS
Latest Healthcare Articles